Publication

Potential of Intestine-Selective FXR Modulation for Treatment of Metabolic Disease

van Zutphen, T., Bertolini, A., de Vries, H. D., Bloks, V. W., de Boer, J. F., Jonker, J. W. & Kuipers, F., 25-Jun-2019, Bile Acids and Their Receptors. Springer, p. 207-234 28 p. (Handbook of Experimental Pharmacology).

Research output: Chapter in Book/Report/Conference proceedingChapterAcademicpeer-review

Copy link to clipboard

Documents

  • Potential of Intestine-Selective FXR Modulation for Treatment of Metabolic Disease

    Final publisher's version, 659 KB, PDF document

    Request copy

DOI

Farnesoid X receptor controls bile acid metabolism, both in the liver and intestine. This potent nuclear receptor not only maintains homeostasis of its own ligands, i.e., bile acids, but also regulates glucose and lipid metabolism as well as the immune system. These findings have led to substantial interest for FXR as a therapeutic target and to the recent approval of an FXR agonist for treating primary biliary cholangitis as well as ongoing clinical trials for other liver diseases. Given that FXR biology is complex, including moderate expression in tissues outside of the enterohepatic circulation, temporal expression of isoforms, posttranscriptional modifications, and the existence of several other bile acid-responsive receptors such as TGR5, clinical application of FXR modulators warrants thorough understanding of its actions. Recent findings have demonstrated remarkable physiological effects of targeting FXR specifically in the intestine (iFXR), thereby avoiding systemic release of modulators. These include local effects such as improvement of intestinal barrier function and intestinal cholesterol turnover, as well as systemic effects such as improvements in glucose homeostasis, insulin sensitivity, and nonalcoholic fatty liver disease (NAFLD). Intriguingly, metabolic improvements have been observed with both an iFXR agonist that leads to production of enteric Fgf15 and increased energy expenditure in adipose tissues and antagonists by reducing systemic ceramide levels and hepatic glucose production. Here we review the recent findings on the role of intestinal FXR and its targeting in metabolic disease.

Original languageEnglish
Title of host publicationBile Acids and Their Receptors
PublisherSpringer
Pages207-234
Number of pages28
ISBN (Electronic)978-3-030-22005-1
ISBN (Print)978-3-030-22004-4
Publication statusE-pub ahead of print - 25-Jun-2019

Publication series

NameHandbook of Experimental Pharmacology
ISSN (Print)0171-2004

ID: 120351531